Ironwood Pharmaceuticals, Inc. (IRWD)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$3.65+0.27%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $603M
- P/E (trailing)
- 4.7
- Forward P/E
- 2.4
- 52-week range
- $1.41 – $5.78
- 52-week change
- +139.47%
- EPS (trailing)
- $0.77
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $296M (−15.73%)
- Net income
- $24.0M
- Operating margin
- 33.3%
- Diluted EPS
- $0.15
- Free cash flow
- $127M
From the company’s annual report on SEC EDGAR.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc.
Headquarters: Boston, United States · 100 employees · ironwoodpharma.com